Published in Neoplasia on October 01, 1999
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer (2008) 1.16
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Int J Environ Res Public Health (2016) 0.75
Green fluorescent protein as a marker for gene expression. Science (1994) 34.55
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (1993) 12.74
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
Mechanisms and biological effects of mismatch repair. Annu Rev Genet (1991) 7.86
Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell (1993) 6.61
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res (1995) 5.26
Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol (1994) 4.43
Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet (1995) 4.01
Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res (1994) 3.63
An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A (1993) 3.07
Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med (1995) 3.07
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res (1993) 2.48
Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev (1995) 2.37
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science (1996) 2.05
Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem (1996) 2.01
An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem Biophys Res Commun (1996) 1.82
Using GFP to see the light. Trends Genet (1995) 1.80
hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene (1997) 1.67
Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res (1996) 1.63
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. J Clin Invest (1996) 1.49
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst (1999) 1.46
Frequent microsatellite instability in primary small cell lung cancer. Cancer Res (1994) 1.44
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol (1996) 1.42
Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res (1997) 1.24
Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res (1998) 1.22
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res (1993) 1.11
A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol Cell Biol (1998) 1.11
Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res (1997) 1.09
Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res (1995) 1.08
Mismatch repair, genetic stability and tumour avoidance. Philos Trans R Soc Lond B Biol Sci (1995) 1.07
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer (1998) 1.00
Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res (1997) 0.95
DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem Biophys Res Commun (1996) 0.93
Mutations in MLH1 are more frequent than in MSH2 in sporadic colorectal cancers with microsatellite instability. Genes Chromosomes Cancer (1997) 0.92
Autocrine transforming growth factor-beta 1 and beta 2 expression is increased by cell crowding and quiescence in colon carcinoma cells. Exp Cell Res (1994) 0.84
Microsatellite instability and other molecular abnormalities in human prostate cancer. Jpn J Cancer Res (1995) 0.84
Microsatellite instability in human testicular germ cell tumours. Br J Cancer (1995) 0.83
Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP. Br J Cancer (1997) 0.83
Microsatellite instability in oral cancer. Int J Cancer (1995) 0.82
Repeat expansion detection analysis of (CAG)n tracts in tumor cell lines, testicular tumors, and testicular cancer families. Cancer Res (1997) 0.81
Modulation of differentiation-related responses in human colon carcinoma cells by protein kinase inhibitor H-7. Anticancer Res (1992) 0.79
Ovarian cancer, from the laboratory to the clinic: challenges for the future. Ann Oncol (1996) 0.78
Growth control in a human colon carcinoma cell line mediated by cell-associated transforming growth factor-alpha (TGF alpha). Exp Cell Res (1993) 0.78
Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line. Biochem Pharmacol (1994) 0.77
Mismatch repair genes matched to several new roles in cancer. J Natl Cancer Inst (1996) 0.76
A physical map of the human genome. Nature (2001) 12.39
Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature (2001) 10.96
A systematic, high-resolution linkage of the cytogenetic and physical maps of the human genome. Nat Genet (2000) 4.78
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci U S A (1989) 4.22
Human immunoglobulin heavy chain genes map to a region of translocations in malignant B lymphocytes. Science (1982) 4.05
Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med (1999) 3.21
Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest (1993) 3.19
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A (2000) 2.81
Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line. Nature (1986) 2.57
General relative risk regression models for epidemiologic studies. Am J Epidemiol (1987) 2.51
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med (1996) 2.51
Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst (1997) 2.45
Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science (1990) 2.40
Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs. Arch Intern Med (1993) 2.36
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
Multiple immunoglobulin switch region homologies outside the heavy chain constant region locus. Nature (1981) 2.18
A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med (1991) 2.14
Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology (1995) 2.03
Duplication and deletion in the human immunoglobulin epsilon genes. Cell (1982) 1.96
Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med (1993) 1.94
The SCL gene product: a positive regulator of erythroid differentiation. EMBO J (1992) 1.90
Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) (2000) 1.88
Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res (1997) 1.82
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
The SIL gene is required for mouse embryonic axial development and left-right specification. Nature (1999) 1.81
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis (1998) 1.75
Characterization of the full length cDNA for murine beta-1,4-galactosyltransferase. Novel features at the 5'-end predict two translational start sites at two in-frame AUGs. J Biol Chem (1988) 1.75
Analysis of gene expression in a complex differentiation hierarchy by global amplification of cDNA from single cells. Curr Biol (1995) 1.67
Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med (1993) 1.66
Evolutionary approach to the question of immunoglobulin heavy chain switching: evidence from cloned human and mouse genes. Proc Natl Acad Sci U S A (1980) 1.64
Localization of the beta-globin gene by chromosomal in situ hybridization. Am J Hum Genet (1984) 1.64
Bovine galactosyltransferase: identification of a clone by direct immunological screening of a cDNA expression library. Proc Natl Acad Sci U S A (1986) 1.59
Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol (1999) 1.59
Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest (1998) 1.58
Burkitt lymphoma cell line carrying a variant translocation creates new DNA at the breakpoint and violates the hierarchy of immunoglobulin gene rearrangement. Mol Cell Biol (1985) 1.56
A chromosome 14 inversion in a T-cell lymphoma is caused by site-specific recombination between immunoglobulin and T-cell receptor loci. Nature (1986) 1.55
Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood (1992) 1.53
Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res (1997) 1.52
Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer (1999) 1.52
Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood (1986) 1.51
Laparoscopic adrenalectomy: a new standard of care. Urology (1997) 1.46
Hypogonadism and obesity in mice with a targeted deletion of the Nhlh2 gene. Nat Genet (1997) 1.41
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res (1994) 1.39
The SCL gene is formed from a transcriptionally complex locus. Mol Cell Biol (1990) 1.38
A stochastic two-stage model for cancer risk assessment. I. The hazard function and the probability of tumor. Risk Anal (1988) 1.36
Structural characterization of SIL, a gene frequently disrupted in T-cell acute lymphoblastic leukemia. Mol Cell Biol (1991) 1.34
Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (1995) 1.33
Molecular cloning and chromosomal localization of the murine homolog of the human helix-loop-helix gene SCL. Proc Natl Acad Sci U S A (1991) 1.32
Analysis of the V(D)J recombination efficiency at lymphoid chromosomal translocation breakpoints. J Biol Chem (2001) 1.29
Hybrid T cell receptor genes formed by interlocus recombination in normal and ataxia-telangiectasis lymphocytes. J Exp Med (1990) 1.27
Interlocus V-J recombination measures genomic instability in agriculture workers at risk for lymphoid malignancies. Proc Natl Acad Sci U S A (1992) 1.27
Translocations that highlight chromosomal regions of differentiated activity. Cancer Genet Cytogenet (1985) 1.26
Opposing effects of the basic helix-loop-helix transcription factor SCL on erythroid and monocytic differentiation. Blood (1996) 1.24
Complex translocation disrupts c-myc regulation in a human plasma cell myeloma. Mol Cell Biol (1988) 1.22
Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med (1998) 1.22
Common mechanism of chromosome inversion in B- and T-cell tumors: relevance to lymphoid development. Science (1986) 1.21
Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg (1994) 1.21
Molecular characterization of NSCL, a gene encoding a helix-loop-helix protein expressed in the developing nervous system. Proc Natl Acad Sci U S A (1992) 1.21
T cell receptor alpha chain genes are located on chromosome 14 at 14q11-14q12 in humans. J Exp Med (1985) 1.17
Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (1998) 1.16
Genetic evidence that Sil is required for the Sonic Hedgehog response pathway. Genesis (2001) 1.15
Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg (2001) 1.14
Expression of the SIL gene is correlated with growth induction and cellular proliferation. Cell Growth Differ (1997) 1.14
Orientation of loci within the human major histocompatibility complex by chromosomal in situ hybridization. Proc Natl Acad Sci U S A (1984) 1.14
MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene (1993) 1.14
Refinement of lymphoma cytogenetics by the chromosome 18q21 major breakpoint region. Blood (1987) 1.14
Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) (2001) 1.14
The urological manifestations of chronic granulomatous disease. J Urol (1992) 1.13
Identification of three new Ig lambda-like genes in man. J Exp Med (1986) 1.12
Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor. J Exp Med (1992) 1.12
Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS (1993) 1.11
NSCL-2: a basic domain helix-loop-helix gene expressed in early neurogenesis. Cell Growth Differ (1992) 1.09
A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer (1998) 1.09
Imaging features of hereditary papillary renal cancers. J Comput Assist Tomogr (1997) 1.08
The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell acute lymphoblastic leukemia activates the BHLHB1 gene. Proc Natl Acad Sci U S A (2000) 1.08
Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med (1994) 1.08
Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab (2001) 1.08
Transcription factor SCL is required for c-kit expression and c-Kit function in hemopoietic cells. J Exp Med (1998) 1.08
The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer. Colorectal Dis (2014) 1.08
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis (1999) 1.07
Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery (1992) 1.06
A stochastic two-stage model for cancer risk assessment. II. The number and size of premalignant clones. Risk Anal (1989) 1.06
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun (2000) 1.06
Regulated expression of the c-myb and c-myc oncogenes during erythroid differentiation. J Cell Biochem (1986) 1.04
Characterization of the breakpoint of a t(14;14)(q11.2;q32) from the leukemic cells of a patient with T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet (1990) 1.03
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol (1993) 1.03
Juxtaposition of the T-cell receptor alpha-chain locus (14q11) and a region (14q32) of potential importance in leukemogenesis by a 14;14 translocation in a patient with T-cell chronic lymphocytic leukemia and ataxia-telangiectasia. Proc Natl Acad Sci U S A (1988) 1.03
Physical interaction between p53 and primary response gene Egr-1. Int J Oncol (2001) 1.02
HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression. J Clin Invest (1996) 1.02
Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther (2001) 1.01
A comparative structural characterization of the human NSCL-1 and NSCL-2 genes. Two basic helix-loop-helix genes expressed in the developing nervous system. J Biol Chem (1992) 1.01
Surgical treatment of localized gastrinoma within the liver: a prospective study. Surgery (1998) 1.01
The absolute number of trans-rearrangements between the TCRG and TCRB loci is predictive of lymphoma risk: a severe combined immune deficiency (SCID) murine model. Cancer Res (1997) 1.00
Heinz body hemolytic anemia from the use of methylene blue in neonates. J Pediatr (1980) 0.99
Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J Clin Oncol (1995) 0.96
Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol (1990) 0.95